C. Homnick

发表

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

A potent cyclic hexapeptide analogue of somatostatin

Ruth F. Nutt, Roger M. Freidinger, Ralph Hirschmann, 1981, Nature.

Non-peptide αvβ3 antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl β-amino acids as aspartic acid replacements

P. Coleman, C. Leu, S. Rodan, 2002 .

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.

H. M. Langford, D. Hazuda, W. Schleif, 2008, Bioorganic & medicinal chemistry letters.

Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.

J. Barrow, R. Freidinger, R. Chang, 2000, Bioorganic & medicinal chemistry letters.

Glucagon releasing activity of a cyclic peptide related to somatostatin.

D. Veber, R. Freidinger, R. Nutt, 2009, International journal of peptide and protein research.

Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.

R. Gould, G. Hartman, S. Gaul, 1999, Journal of medicinal chemistry.

Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.

P. Coleman, C. Leu, S. Rodan, 2002, Bioorganic & medicinal chemistry letters.

A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones

B. E. Evans, D. Veber, K. Rittle, 1985 .

A Stereocontrolled Synthesis of Hydroxyethylene Dipeptide Isosteres Using Novel, Chiral Aminoalkyl Epoxides and γ-(Aminoalkyl) γ-Lactones.

B. E. Evans, D. Veber, K. Rittle, 1986 .

Inhibition of acute nociceptive responses in rat spinal cord by a bradykinin B1 receptor antagonist.

M. Bock, R. M. Dipardo, R. Chang, 2005, European journal of pharmacology.

Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors.

C. Coburn, J. Vacca, S. D. Lewis, 2000, Bioorganic & medicinal chemistry letters.

Benzodiazepines as potent and selective bradykinin B1 antagonists.

Tsing-Bau Chen, M. Bock, R. M. Dipardo, 2003, Journal of medicinal chemistry.

L-156,602, a C5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348. Fermentation, isolation and structure determination.

O. Hensens, C. Schwartz, S. Currie, 1991 .

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

D. Hazuda, Jiunn H. Lin, W. Schleif, 2005, Bioorganic & medicinal chemistry letters.

Asymmetric Synthesis of α,α-Difluoro-β-amino Acid Derivatives from Enantiomerically Pure N-tert-Butylsulfinimines

R. Ball, C. Homnick, N. Tsou, 2002 .

Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors.

C. Coburn, J. Vacca, S. D. Lewis, 2000, Bioorganic & medicinal chemistry letters.

In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia

J. Barrow, K. Rittle, R. Freidinger, 2000 .

Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.

Michael Rowley, Cristina Gardelli, Marco Ferrara, 2007, Journal of medicinal chemistry.

9-hydroxyazafluorenes and their use in thrombin inhibitors.

Youwei Yan, B. Wong, P. Nantermet, 2005, Journal of medicinal chemistry.

Inhibition of a mitotic motor protein: where, how, and conformational consequences.

Lawrence C Kuo, Youwei Yan, L. Kuo, 2004, Journal of molecular biology.

Total synthesis of nonpeptidal cholecystokinin antagonists from Aspergillus alliaceus

M. Bock, R. M. Dipardo, R. Freidinger, 1987 .

A synthesis of statine utilizing an oxidative route to chiral .alpha.-amino aldehydes

B. E. Evans, K. Rittle, G. Ponticello, 1982 .

Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1987, Journal of medicinal chemistry.

Complestatin to chloropeptin I via a quantitative acid catalyzed rearrangement. Absolute stereochemical determination of complestatin.

Scott K. Smith, M. Holloway, S. Gould, 1998 .

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

A new amine resolution method and its application to 3-aminobenzodiazepines

B. E. Evans, D. Veber, K. Rittle, 1987 .

A New Amine Resolution Method and Its Application to 3‐Aminobenzodiazepines.

B. E. Evans, D. Veber, K. Rittle, 1987 .

Synthesis of thyrotropin-releasing hormone analogues with selective central nervous system effects.

D. Veber, R. Nutt, B. Arison, 1981, Journal of medicinal chemistry.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

A simple and inexpensive synthesis of 4-(aminomethyl)-L-phenylalanine

W. F. Hoffman, G. Stokker, C. Homnick, 1993 .

Design of proteolytically-stable, peptidal renin inhibitors and determination of their fate in vivo.

D. Veber, J. Boger, E. Ulm, 1985, Regulatory peptides. Supplement.

Selective and controlled hydrolysis of chloropeptin I. HIV-1 integrase activity of fragments

M. Patane, M. Sardana, P. Felock, 1998 .

Large-scale synthesis of a cyclic hexapeptide analog of somatostatin

D. Veber, R. Freidinger, W. L. Whitter, 1987 .

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.

J. Barrow, K. Rittle, R. Freidinger, 2000, Journal of medicinal chemistry.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

J. Huff, M. Bogusky, S. Graham, 2001, Journal of the American Chemical Society.

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4- dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

W. M. Sanders, P. Anderson, W. Schleif, 1994 .

Nonreducible cyclic analogues of somatostatin

D. Veber, F. W. Holly, R. Hirschmann, 1976 .